Attorney Docket No. 36180-102911

Client Reference: 205664546

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Confirmation No. 5258

Walsh et al.

Group Art Unit: Unassigned

Application No. 10/570,836

Examiner: Unassigned

Filed: March 3, 2006

For: ASSAY FOR DIABETES

#### INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT Attn: DO/EO/US Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing  $\boxtimes$ date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

## Copies of the References

$\boxtimes$	Copies of all of the references listed on the enclosed Form 1449 are enclosed herewith.
	Copies of U.S. patents and published U.S. patent applications that are listed on the accompanying Form 1449 are not enclosed herewith. However, copies of all other references identified on the accompanying Form 1449 are enclosed herewith.
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the

degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).  $\boxtimes$ A conv of the international search report is enclosed herewith. Fees No fee is owed by the applicant(s). The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith. **Authorization to Charge Additional Fees** If any additional fees are owed in connection with this communication, please charge X Deposit Account No. 12-0913. Respectfully submitted, Alice O. Martin, Reg. No. 35,601 **BARNES & THORNBURG LLP** P.O. Box 2786 Chicago, Illinois 60690-2786 (312) 357-1313 (telephone) (312) 759-5646 (facsimile) Date: December 13, 2006

Client Ref.: 205664546

### **CERTIFICATION UNDER 37 CFR 1.8**

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being electronically filed on the date shown below via EFS WEB and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 13, 2006

.

CHDS01 AOM 365995v1

Please type a plus sign (+) Inside this box ->	+
, todada typo a piao orgin ( ) moreo time won	

Substitute for form 1449A/B/PTO

Sheet

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 1

Complete if Known				
Application Number	10/570,836			
Filing Date	March 3, 2006			
First Named Inventor	Walsh, Bradley John			
Group Art Unit	Unassigned			
Examiner Name	Unassigned			
Attorney Docket Number	36180-102911			

U.S. PATENT DOCUMENTS							
Examiner Initials		U.S. Patent Document					
	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
	+ +		<del>                                     </del>				
	<del>  </del>		+ +		<del></del>	l .	
			1				
						1	

		Foreign Patent Document			IGN PATENT DOCUMENTS		Translation	
Examiner Initials	r Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*
	AA	wo	01/90155	A2	Curagen Corporation	Nov. 29, 2001	T	
	AB	wo	03/060149	A2	Curagen Corporation	Jul. 24, 2003	<u> </u>	_
				ļ —			1	┢
								$\vdash$
-								
								₩
							<u> </u>	
	<u> </u>	$\vdash$					+	╁
								二
		1		<u> </u>				₩
							+	$\vdash$
				L			1	

CHDS01 AOM 369990v1

Date Considered **Examiner Signature** 

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).